Nectin Therapeutics, Ltd., the parent company of Guangzhou Nectin Pharmaceutical Co., Ltd., a project invested by GIBF2, is a biotechnology company developing novel immunotherapies and antibody-drug conjugates (ADC) to address tumor resistance. The company recently announced a global exclusive license agreement with Immunome Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, for a monoclonal antibody molecule. Under the terms of the agreement, Nectin granted Immunome an exclusive, worldwide, all-fields license to monoclonal antibodies that are directed to a single undisclosed target. Immunome will be responsible for the research, development, manufacturing and commercialization of products incorporating these antibodies. Nectin will receive an upfront payment and will be eligible for milestones and royalties.

Fabian Tenenbaum, Chief Executive Officer of Nectin Therapeutics, stated that this agreement allows Nectin to realize value while further pursuing and enabling the focus on its first-in-class anti-PVR program (NTX1088) as well as advance its novel ADCs into clinical development.

Clay Siegall, PhD, President and Chief Executive Officer of Immunome ,stated that Immunome’s long-term vision remains centered on a broad pipeline of targeted therapies, particularly ADCs against novel targets. Focused business development activity complements its highly productive internal discovery efforts and has led to an advancing pipeline of product candidates.

Jack Higgins, PhD, Chief Scientific Officer of Immunome, added that successful ADC development requires addressing the unique biology of each target with appropriate antibodies, linkers and payloads. Immunome’s research team has identified multiple promising ADC targets. The team have also established a toolbox that includes multiple linkers, differentiated proprietary TOP1 inhibitor and numerous antibodies. Immunome believe that the next generation of ADCs will bring tremendous benefit to cancer patients. Immunome believes that the next generation of transformative antibody-drug conjugates (ADCs) will address new targets by combining high-quality antibodies with innovative linker-payload technologies.

About Nectin Therapeutics, Ltd.
Nectin Therapeutics is a clinical stage biotechnology company devoted to transforming the lives of cancer patients by leveraging unique insights into Nectin pathways to develop the next generation of immune oncology (IO) therapies and antibody drug conjugates (ADCs). The company's differentiated therapies have the potential to set new standards for efficacy and patient response rates across various difficult-to-treat cancers. Nectin's technology addresses major escape mechanisms of current IO therapies through a diverse pipeline of novel monoclonal antibodies and antibody drug conjugates (ADCs). It has a world-class scientific and management team with deep experience in oncology drug development and successful track records in building biotechnology companies and developing innovative therapies.
Nectin Therapeutics is a venture-backed, privately held company, funded by aMoon Fund, Peregrine Ventures, IBF, Integra Holdings, the Myeloma Investment Fund (MIF), GIBF2 and the Cancer Focus Fund.

About Immunome, Inc.
Immunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted therapies designed to improve outcomes for cancer patients. We are advancing an innovative portfolio of therapeutics, drawing on leadership that previously played key roles in the design, development and commercialization of cutting-edge targeted cancer therapies, including antibody-drug conjugates (ADCs). For more information, visit www.immunome.com.